吸入RVT-1601治疗特发性肺纤维化慢性咳嗽的2B期研究:SCENIC试验
这项多中心、随机、安慰剂对照2B期研究评估吸入RVT-1601治疗特发性肺纤维化(IPF)慢性咳嗽的疗效与安全性,108例患者随机接受10、40、80 mg每日三次或安慰剂治疗12周。因COVID-19疫情提前终止,结果显示RVT-1601各组在24小时咳嗽计数、咳嗽严重度和咳嗽特异性生活质量方面均未优于安慰剂,治疗总体耐受良好。
要点
- 吸入RVT-1601(10、40、80 mg每日三次)未改善IPF患者24小时咳嗽计数。
- 咳嗽严重度和咳嗽特异性生活质量亦无显著优于安慰剂。
- 治疗总体耐受良好,但研究因COVID-19疫情提前终止。
核心结论
- 吸入RVT-1601(10、40、80 mg每日三次)治疗IPF患者慢性咳嗽未优于安慰剂。
研究设计与样本
- 多中心、随机、安慰剂对照2B期研究,IPF伴慢性咳嗽≥8周患者按1:1:1:1随机接受10、40、80 mg RVT-1601每日三次或安慰剂治疗12周。
- 共108例患者接受治疗(平均年龄71.0岁,男性62.9%),RVT-1601 10 mg组29例、40 mg组25例、80 mg组27例、安慰剂组27例;61.1%(66例)完成双盲治疗。
- 研究因COVID-19疫情影响提前终止。
主要发现
- 主要终点(基线至治疗结束log转换24小时咳嗽计数的变化)在各RVT-1601组与安慰剂组间无统计学显著差异。
- 关键次要终点(咳嗽严重度及咳嗽特异性生活质量较基线变化)在各RVT-1601组与安慰剂组间无统计学显著差异。
- 安慰剂组24小时平均咳嗽计数较基线的平均百分比变化为27.7%。
- 治疗总体耐受良好。
临床怎么用
- 吸入RVT-1601(10、40、80 mg每日三次)未显示对IPF慢性咳嗽的获益,不支持用于该适应症。
局限性
- 研究因COVID-19疫情提前终止,可能影响统计效能。
- 仅61.1%的患者完成双盲治疗,脱落率较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Chronic cough remains a major and often debilitating symptom for patients with idiopathic pulmonary fibrosis (IPF). In a phase 2A study, inhaled RVT-1601 (cromolyn sodium) reduced daytime cough and 24-hour average cough counts in patients with IPF. Objectives: To determine the efficacy, safety, and optimal dose of inhaled RVT-1601 for the treatment of chronic cough in patients with IPF. Methods: In this multicenter, randomized, placebo-controlled phase 2B study, patients with IPF and chronic cough for ⩾8 weeks were randomized (1:1:1:1) to receive 10, 40, and 80 mg RVT-1601 three times daily or placebo for 12 weeks. The primary endpoint was change from baseline to end of treatment in log-transformed 24-hour cough count. Key secondary endpoints were change from baseline in cough severity and cough-specific quality of life. Safety was monitored throughout the study. Measurements and Main Results: The study was prematurely terminated owing to the impact of the coronavirus disease (COVID-19) pandemic. Overall, 108 patients (mean age 71.0 years, 62.9% males) received RVT-1601 10 mg (n = 29), 40 mg (n = 25), 80 mg (n = 27), or matching placebo (n = 27); 61.1% (n = 66) completed double-blind treatment. No statistically significant difference was observed in the least-square mean change from baseline in log-transformed 24-hour average cough count, cough severity, and cough-specific quality of life score between the RVT-1601 groups and the placebo group. The mean percentage change from baseline in 24-hour average cough count was 27.7% in the placebo group. Treatment was generally well tolerated. Conclusions: Treatment with inhaled RVT-1601 (10, 40, and 80 mg three times a day) did not provide benefit over placebo for the treatment of chronic cough in patients with IPF.
引用
- Martinez FJ, Wijsenbeek MS, Raghu G, et al. Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). Am J Respir Crit Care Med. 2022. PMID: 35050837. doi:10.1164/rccm.202106-1485OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。